Filing Flows › Septerna (SEPN) › Recalls, complaints & regulation
Septerna (SEPN): clinical trials
Septerna (SEPN) beyond its filings: 1 active clinical trial.
Septerna's latest quarter
Septerna, Q2 2026: revenue $26.7M (225× year over year), operating margin -62.9%, net loss $13.0M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Septerna have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.